Evidence map›Paper›PMID 31406955›Full record

ArticleJCO precision oncology2019

Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology.

Xiaowen Liu, Zongliang Yue, Yimou Cao, Lauren Taylor, Qing Zhang, Sung W Choi, Samir Hanash, Sawa Ito, Jake Y Chen, Huanmei Wu and 1 more

Open access · hybridAbstract read
In one paragraph

Article in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Xiaowen Liu *Indiana University School of Informatics and Computing, Indianapolis, IN.
Zongliang Yue *University of Alabama at Birmingham School of Medicine, Birmingham, AL.
Yimou Cao *Indiana University School of Informatics and Computing, Indianapolis, IN.
Lauren TaylorIndiana University School of Medicine, Indianapolis, IN.
Qing ZhangFred Hutchinson Cancer Research Center, Seattle, WA.
Sung W ChoiUniversity of Michigan, Ann Arbor, MI.
Samir HanashMD Anderson Cancer Center, Houston, TX.
Sawa Ito *National Heart, Lung, and Blood Institute, Bethesda, MD.
Jake Y Chen *University of Alabama at Birmingham School of Medicine, Birmingham, AL.
Huanmei Wu *Indiana University School of Informatics and Computing, Indianapolis, IN.
Sophie Paczesny *Indiana University School of Medicine, Indianapolis, IN.
Indiana University – Purdue University Indianapolis · USIndiana University School of MedicineUniversity of Alabama at Birmingham · USFred Hutch Cancer Center · USNational Heart Lung and Blood Institute · USThe University of Texas MD Anderson Cancer Center · USUniversity of Michigan–Ann Arbor · US

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host DiseaseR01CA168814 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PACZESNY, SOPHIE · 2013 to 2024
$3.0M
NCATS NIH HHS UL1 TR001108NCI NIH HHS R01 CA168814
6 · The paper itself

Abstract

purposeAs a tumor immunotherapy, allogeneic hematopoietic cell transplantation with subsequent donor lymphocyte injection (DLI) aims to induce the graft-versus-tumor (GVT) effect but often also leads to acute graft-versus-host disease (GVHD). Plasma tests that can predict the likelihood of GVT without GVHD are still needed. PATIENTS AND

methodsWe first used an intact-protein analysis system to profile the plasma proteome post-DLI of patients who experienced GVT and acute GVHD for comparison with the proteome of patients who experienced GVT without GVHD in a training set. Our novel six-step systems biology analysis involved removing common proteins and GVHD-specific proteins, creating a protein-protein interaction network, calculating relevance and penalty scores, and visualizing candidate biomarkers in gene networks. We then performed a second proteomics experiment in a validation set of patients who experienced GVT without acute GVHD after DLI for comparison with the proteome of patients before DLI. We next combined the two experiments to define a biologically relevant signature of GVT without GVHD. An independent experiment with single-cell profiling in tumor antigen-activated T cells from a patient with post-hematopoietic cell transplantation relapse was performed.

resultsThe approach provided a list of 46 proteins in the training set, and 30 proteins in the validation set were associated with GVT without GVHD. The combination of the two experiments defined a unique 61-protein signature of GVT without GVHD. Finally, the single-cell profiling in activated T cells found 43 of the 61 genes. Novel markers, such as RPL23, ILF2, CD58, and CRTAM, were identified and could be extended to other antitumoral responses.

conclusionOur multiomic analysis provides, to our knowledge, the first human plasma signature for GVT without GVHD. Risk stratification on the basis of this signature would allow for customized treatment plans.

Identifiers

PMID31406955
PMCPMC6690359
OpenAlexW2945260061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.